Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1026706

Drug Profile

BI 1026706

Alternative Names: BI-1026706

Latest Information Update: 19 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim Pharmaceuticals
  • Class Analgesics; Antirheumatics; Eye disorder therapies
  • Mechanism of Action Bradykinin B1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema
  • Phase I Chronic obstructive pulmonary disease
  • No development reported Osteoarthritis; Postoperative pain

Most Recent Events

  • 19 Sep 2019 Phase I for Chronic obstructive pulmonary disease is still ongoing in Denmark, Germany, Sweden and United Kingdom
  • 17 May 2019 Adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
  • 17 May 2019 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Chronic obstructive pulmonary disease (In volunteers) presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top